{
    "Clinical Trial ID": "NCT01463007",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Radiation",
        "  AccuBoost APBI- 34.0 Gy in 10fx",
        "  Accelerated partial breast irradiation: Accuboost APBI 34.0 Gy in 10 fractions",
        "INTERVENTION 2: ",
        "  Extended to 5 Years of Follow Up-Rhode Island Hospital Only",
        "  Follow up has been extended to include follow up visits at 2,6 weeks and at 4,6,12,18,24 months then annually (+/- 6 months) for an additional 3 years for a total of approximately 5 years of follow up."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  A confirmed histological diagnosis of invasive breast carcinoma or DCIS",
        "  Age greater or equal to 50 years old",
        "  Life expectancy > 6 months",
        "  Treated by breast conserving surgery with axillary node dissection or sentinel lymph node biopsy",
        "  Pathologic tumor size less than or equal to 2 cm",
        "  Invasive ductal, mucinous, tubular or colloid histology",
        "  Estrogen receptor positive for invasive carcinoma.",
        "  Unifocal/unicentric disease",
        "  Negative surgical margins greater than or equal to 2 mm",
        "  Pathologic lymph node negative",
        "  No evidence of lymphovascular invasion",
        "  ECOG performance status of 0 or 1 (Appendix 1)",
        "  Informed consent signed.",
        "Exclusion Criteria:",
        "  Known BRCA 1/2 Mutation; (BRCA 1 and 2 testing is not required)",
        "  Autoimmune disorder",
        "  Pregnancy",
        "  Breast implants",
        "  Psychiatric or addictive disorder that would preclude attending follow-up",
        "  Neoadjuvant chemotherapy (adjuvant chemotherapy is permitted)",
        "  Suspicious remaining microcalcification on post-surgery mammogram (unless biopsy proven benign)",
        "  Lobular features on histology (pure or mixed) or sarcoma histology",
        "  Node positive on axillary dissection or in the sentinel lymph node biopsy;",
        "  Extensive in situ carcinoma (EIC)",
        "  Multicentric or multifocal disease",
        "  Paget's disease of the nipple",
        "  Distant metastases",
        "  Lumpectomy cavity not well visualized on AccuBoost imaging",
        "  Lumpectomy cavity with 1cm margin (PTV) not adequately encompassed by any applicator (PTV > 6cm)",
        "  Breast separation with compression > 7cm.",
        "  Overlap of skin between orthogonal treatment axes."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Early and Intermediate Toxicity",
        "  Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 (Appendix 4). Acute side effects are any side effects occurring within 3 months of treatment. Intermediate side effects are any side effects occurring between 3 months and 2 years. This is reported in the outcome table.",
        "  Time frame: 2 years",
        "Results 1: ",
        "  Arm/Group Title: Radiation",
        "  Arm/Group Description: AccuBoost APBI- 34.0 Gy in 10fx",
        "  Accelerated partial breast irradiation: Accuboost APBI 34.0 Gy in 10 fractions",
        "  Overall Number of Participants Analyzed: 41",
        "  Measure Type: Number",
        "  Unit of Measure: participants  40",
        "Results 2: ",
        "  Arm/Group Title: Extended to 5 Years of Follow Up-Rhode Island Hospital Only",
        "  Arm/Group Description: Follow up has been extended to include follow up visits at 2,6 weeks and at 4,6,12,18,24 months then annually (+/- 6 months) for an additional 3 years for a total of approximately 5 years of follow up.",
        "  Overall Number of Participants Analyzed: 28",
        "  Measure Type: Number",
        "  Unit of Measure: participants  28"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/41 (2.44%)",
        "  Infection  1/41 (2.44%)",
        "  Creatinine  1/41 (2.44%)",
        "  Hypokalemia  1/41 (2.44%)",
        "  Bicarbonate  1/41 (2.44%)",
        "  SGOT  1/41 (2.44%)",
        "  Alkaline Phosphatase value  1/41 (2.44%)",
        "  Hyperbilirubineamia  1/41 (2.44%)",
        "  Hypoalbuminemia  1/41 (2.44%)",
        "  Leukocytes  1/41 (2.44%)",
        "  Hemoglobin  1/41 (2.44%)",
        "  Neutrophils  1/41 (2.44%)",
        "  INR  1/41 (2.44%)",
        "  PTT  1/41 (2.44%)",
        "Adverse Events 2:",
        "   "
    ]
}